The Zhitong Finance App learned that Bank of America Securities released a research report stating that the earnings forecast per share for 2024 to 2026 will be adjusted by -3%/100%/4%, respectively, due to changes in revenue from BeiGene (06160). In view of the company's smooth progress in drug pipeline development, the target price for BeiGene was raised from HK$103.5 to HK$108.27, and the “neutral” rating was reaffirmed.

The bank pointed out that in response to the US Food and Drug Administration (FDA) approval for the use of tirelizumab developed by BeiGene and the strong sample sales performance of related drugs in January, the bank raised the company's overall revenue forecast for 2024 to 2026 by 0.9%/1.2%/0.7%, respectively.